| Literature DB >> 32883160 |
Guilherme R de Jesús1, Ashley E Benson2, Cecilia B Chighizola3, Savino Sciascia4, David W Branch2.
Abstract
Obstetric antiphospholipid syndrome (APS) remains a clinical challenge for practitioners, with several controversial points that have not been answered so far. This Obstetric APS Task Force met on the 16th International Congress on Antiphospholipid Antibodies in Manchester, England, to discuss about treatment, diagnostic and clinical aspects of the disease. This report will address evidence-based medicine related to obstetric APS, including limitations on our current management, the relationship between antibodies against domain 1 of β2GPI and obstetric morbidity, hydroxychloroquine use in patients with obstetric APS and factors associated with thrombosis after obstetric APS. Finally, future directions for better understanding this complex condition are also reported by the Task Force coordinators.Entities:
Keywords: Antiphospholipid syndrome; anti-β2GPI domain 1 antibodies; antiphospholipid antibodies; hydroxychloroquine; thrombosis
Mesh:
Substances:
Year: 2020 PMID: 32883160 DOI: 10.1177/0961203320954520
Source DB: PubMed Journal: Lupus ISSN: 0961-2033 Impact factor: 2.911